Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Royalty Pharma
RPRX
Royalty Pharma
Royalty Revenue Will Contract Amid Strict Pricing And Debt Pressures
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
18 Apr 25
Updated
16 Aug 25
0
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$32.19
11.6% overvalued
intrinsic discount
16 Aug
US$35.92
Loading
1Y
31.8%
7D
0.2%
Author's Valuation
US$32.2
11.6% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$32.2
11.6% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
0
3b
2017
2019
2021
2023
2025
2027
2028
Revenue US$2.6b
Earnings US$671.9m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
12.81%
Pharma revenue growth rate
0.57%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$671.95m
Earnings '28
x
22.63x
PE Ratio '28
=
US$15.20b
Market Cap '28
US$15.20b
Market Cap '28
/
388.06m
No. shares '28
=
US$39.18
Share Price '28
US$39.18
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$32.19
Fair Value '25
